APUS · Apimeds Pharmaceuticals US Inc
United States · RS rating 79 · As of 2026-10-14
| Price | 4.58 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 79 / 99 / 99 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 38 / 36 / 30 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | +47.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +88.2% |
| Market cap (USD) | $19.0M |